Sabag Mark 4
4 · TEVA PHARMACEUTICAL INDUSTRIES LTD · Filed Dec 11, 2025
Insider Transaction Report
Form 4
Sabag Mark
See "Remarks"
Transactions
- Exercise/Conversion
Ordinary Shares
2025-12-09$18.61/sh+118,724$2,209,454→ 269,720 total - Sale
Ordinary Shares
2025-12-09$28.75/sh−118,724$3,413,078→ 150,996 total - Sale
Ordinary Shares
2025-12-09$28.70/sh−98,168$2,817,677→ 52,828 total - Exercise/Conversion
Stock Options (right to buy)
2025-12-09−118,724→ 0 totalExercise: $18.61Exp: 2028-02-09→ Ordinary Shares (118,724 underlying)
Footnotes (4)
- [F1]The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.705 to $28.845, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.675 to $28.745, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.
- [F4]Stock options were granted on February 9, 2018, with 39,574 vested on each of February 9, 2020, February 9, 2021 and February 9, 2022.